Examples include natalizumab against α4β1 integrin in immune-mediated conditions such as multiple sclerosis and Crohn’s disease [60,61], and alemtuzumab against the lymphocyte antigen CD52, also for multiple sclerosis [62]; while antibodies in clinical trials include anti-Nogo A against myelin protein Nogo-A for the treatment of spinal cord injury [63]. This evidence concerns the gene RTN4 and multiple sclerosis.